Kisunla (donanemab-azbt) for the Treatment of Early Alzheimer’s Disease, US
Kisunla™ (donanemab-azbt) is a disease-modifying therapy (DMT) for adults with early symptomatic Alzheimer’s disease (AD), encompassing those with mild cognitive …
Projects
-
-
Modeyso (dordaviprone) for the Treatment of Diffuse Midline Glioma, US
Modeyso™ (dordaviprone) is indicated for the treatment of adult and paediatric patients aged one year and older with diffuse midline …
-
Nucala (mepolizumab) for the Treatment of Hypereosinophilic Syndrome (HES), UK
Nucala® (mepolizumab) is the first biologic therapy indicated for the treatment of hypereosinophilic syndrome (HES) in adult and paediatric patients …
-
Jascayd (nerandomilast) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF), US
Jascayd® (nerandomilast/BI 1015550) is a phosphodiesterase 4 (PDE4) inhibitor developed by Boehringer Ingelheim for the treatment of adults with idiopathic …
-
Briumvi (ublituximab-xiiy) for the Treatment of Multiple Sclerosis, US
Briumvi™ (ublituximab-xiiy) is indicated for the treatment of adults with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, …
-
EKTERLY (sebetralstat) for the Treatment of Hereditary Angioedema, USA
EKTERLY® (sebetralstat) is a plasma kallikrein inhibitor indicated for the treatment of acute hereditary angioedema (HAE) attacks in adults and in children aged 12 …
-
IBTROZI for the Treatment of Non-small Cell Lung Cancer, US
IBTROZI™ (taletrectinib) is a tyrosine kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic non-small cell …
-
Breyanzi for the Treatment of Large B-cell Lymphoma, US
Breyanzi (lisocabtagene maraleucel) is a CD19-directed chimeric antigen receptor (CAR) T-cell immunotherapy indicated for the treatment of adult patients with …
-
FORZINITY (elamipretide) for Muscle Strength in Barth syndrome, USA
FORZINITY™ (elamipretide HCl) is indicated to enhance muscle strength in adult and paediatric patients with Barth syndrome who weigh at …
-
HERNEXEOS (zongertinib tablets) for the Treatment of HER-2 Mutant Advanced NSCLC, USA
HERNEXEOS® (zongertinib tablets) is a selective tyrosine kinase inhibitor (TKI) indicated for the treatment of adult patients with unresectable or …
-
ENHERTU (fam-trastuzumab deruxtecan-nxki) for the treatment of HER2 positive advanced gastric cancer
Enhertu® (fam-trastuzumab deruxtecan-nxki) is an antibody-drug conjugate indicated for the treatment of various types of cancer, including gastric, breast, and …
-
PALSONIFY (paltusotine) for the Treatment of Acromegaly, USA
PALSONIFY™ (paltusotine) is a first-in-class, nonpeptide somatostatin receptor type 2 (SSTR2) agonist indicated as a first-line treatment for adults with …
-
COBENFY for the Treatment of Schizophrenia, US
COBENFY™ (xanomeline and trospium chloride) is an antipsychotic drug combining xanomeline, a muscarinic acetylcholine receptor (mAChR) agonist, and trospium chloride, …
-
BALVERSA for the Treatment of Urothelial Carcinoma, US
BALVERSA® (erdafitinib) is a fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for the treatment of patients with locally advanced or …
-
Iqirvo for the Treatment of Primary Biliary Cholangitis, US
Iqirvo® (elafibranor) is a first-in-class peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of primary biliary cholangitis (PBC) in …
